📊 TPST Key Takeaways
Is Tempest Therapeutics, Inc. (TPST) a Good Investment?
Tempest is a clinical-stage biotech facing imminent liquidity crisis with -$26.8M annual cash burn against only $7.7M cash reserves, yielding sub-4-month runway. Minimal revenue generation ($203K) combined with massive operating losses (-$26.6M) and unsustainable cash depletion trajectory creates existential funding risk that overshadows any pipeline potential.
Why Buy Tempest Therapeutics, Inc. Stock? TPST Key Strengths
- Moderate debt-to-equity ratio (0.63x) limits financial leverage
- Short-term liquidity position adequate relative to current liabilities (2.50x current ratio)
- Continued insider filings suggest ongoing operational engagement and development activities
TPST Stock Risks: Tempest Therapeutics, Inc. Investment Risks
- Critical cash depletion: 3-4 months of runway at current -$26.8M annual burn rate
- Negligible revenue ($203K) with no visible commercial traction or monetization pathway
- Structurally unsustainable: Operating losses of -$26.6M dwarf any near-term revenue potential, requiring either transformational catalysts or dilutive capital raise
- Typical biotech clinical/regulatory risk compounded by severely constrained financial position
Key Metrics to Watch
- Quarterly cash position and monthly burn rate trajectory
- Capital raise announcements or financing activities
- Clinical trial advancement and regulatory milestones
Tempest Therapeutics, Inc. (TPST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.50x current ratio provides a solid financial cushion.
TPST Profit Margin, ROE & Profitability Analysis
TPST vs Healthcare Sector: How Tempest Therapeutics, Inc. Compares
How Tempest Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tempest Therapeutics, Inc. Stock Overvalued? TPST Valuation Analysis 2026
Based on fundamental analysis, Tempest Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tempest Therapeutics, Inc. Balance Sheet: TPST Debt, Cash & Liquidity
TPST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tempest Therapeutics, Inc.'s revenue has grown significantly by 136% over the 5-year period, indicating strong business expansion. The most recent EPS of $-19.50 indicates the company is currently unprofitable.
TPST Revenue Growth, EPS Growth & YoY Performance
TPST Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2018 | $55.0K | -$5.7M | N/A |
| Q2 2018 | $81.0K | -$7.7M | N/A |
| Q1 2018 | $63.0K | -$7.4M | N/A |
| Q3 2017 | $56.0K | -$9.3M | N/A |
| Q2 2017 | $84.0K | -$18.2M | N/A |
| Q1 2017 | $63.0K | -$14.9M | N/A |
| Q3 2016 | $75.0K | -$17.9M | N/A |
| Q2 2016 | $30.0K | -$17.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tempest Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TPST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tempest Therapeutics, Inc. (CIK: 0001544227)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TPST
What is the AI rating for TPST?
Tempest Therapeutics, Inc. (TPST) has an AI rating of STRONG SELL with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TPST's key strengths?
Claude: Moderate debt-to-equity ratio (0.63x) limits financial leverage. Short-term liquidity position adequate relative to current liabilities (2.50x current ratio).
What are the risks of investing in TPST?
Claude: Critical cash depletion: 3-4 months of runway at current -$26.8M annual burn rate. Negligible revenue ($203K) with no visible commercial traction or monetization pathway.
What is TPST's revenue and growth?
Tempest Therapeutics, Inc. reported revenue of $203.0K.
Does TPST pay dividends?
Tempest Therapeutics, Inc. does not currently pay dividends.
Where can I find TPST SEC filings?
Official SEC filings for Tempest Therapeutics, Inc. (CIK: 0001544227) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TPST's EPS?
Tempest Therapeutics, Inc. has a diluted EPS of $-6.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TPST a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tempest Therapeutics, Inc. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TPST stock overvalued or undervalued?
Valuation metrics for TPST: ROE of -393.9% (sector avg: 15%), net margin of -12,936.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TPST stock in 2026?
Our dual AI analysis gives Tempest Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TPST's free cash flow?
Tempest Therapeutics, Inc.'s operating cash flow is $-26.8M, with capital expenditures of $0.0. FCF margin is -13,211.8%.
How does TPST compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -12,936.9% (avg: 12%), ROE -393.9% (avg: 15%), current ratio 2.50 (avg: 2).